These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 28346474)
1. The microRNA-205-5p is correlated to metastatic potential of 21T series: A breast cancer progression model. Stankevicins L; Barat A; Dessen P; Vassetzky Y; de Moura Gallo CV PLoS One; 2017; 12(3):e0173756. PubMed ID: 28346474 [TBL] [Abstract][Full Text] [Related]
2. Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer. Tan X; Li Z; Ren S; Rezaei K; Pan Q; Goldstein AT; Macri CJ; Cao D; Brem RF; Fu SW Breast Cancer Res; 2019 Aug; 21(1):89. PubMed ID: 31391072 [TBL] [Abstract][Full Text] [Related]
3. The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer. Krstic M; Macmillan CD; Leong HS; Clifford AG; Souter LH; Dales DW; Postenka CO; Chambers AF; Tuck AB BMC Cancer; 2016 Aug; 16(1):671. PubMed ID: 27553211 [TBL] [Abstract][Full Text] [Related]
4. Human 21T breast epithelial cell lines mimic breast cancer progression in vivo and in vitro and show stage-specific gene expression patterns. Souter LH; Andrews JD; Zhang G; Cook AC; Postenka CO; Al-Katib W; Leong HS; Rodenhiser DI; Chambers AF; Tuck AB Lab Invest; 2010 Aug; 90(8):1247-58. PubMed ID: 20458274 [TBL] [Abstract][Full Text] [Related]
5. In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas. Maroni P; Puglisi R; Mattia G; Carè A; Matteucci E; Bendinelli P; Desiderio MA Carcinogenesis; 2017 May; 38(5):492-503. PubMed ID: 28334277 [TBL] [Abstract][Full Text] [Related]
6. Role of miR-139 as a surrogate marker for tumor aggression in breast cancer. Dai H; Gallagher D; Schmitt S; Pessetto ZY; Fan F; Godwin AK; Tawfik O Hum Pathol; 2017 Mar; 61():68-77. PubMed ID: 27864119 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. Li S; Meng H; Zhou F; Zhai L; Zhang L; Gu F; Fan Y; Lang R; Fu L; Gu L; Qi L Pathol Res Pract; 2013 Mar; 209(3):179-83. PubMed ID: 23399321 [TBL] [Abstract][Full Text] [Related]
8. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636 [TBL] [Abstract][Full Text] [Related]
9. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer. Tan X; Fu Y; Chen L; Lee W; Lai Y; Rezaei K; Tabbara S; Latham P; Teal CB; Man YG; Siegel RS; Brem RF; Fu SW Oncotarget; 2016 Jan; 7(1):293-307. PubMed ID: 26588055 [TBL] [Abstract][Full Text] [Related]
10. Stage of breast cancer progression influences cellular response to activation of the WNT/planar cell polarity pathway. MacMillan CD; Leong HS; Dales DW; Robertson AE; Lewis JD; Chambers AF; Tuck AB Sci Rep; 2014 Sep; 4():6315. PubMed ID: 25204426 [TBL] [Abstract][Full Text] [Related]
11. The MicroRNA-382-5p/MXD1 Axis Relates to Breast Cancer Progression and Promotes Cell Malignant Phenotypes. Zhang X; Zhao H; Zhang Y; Yang X; Zhang J; Yi M; Zhang C J Surg Res; 2020 Feb; 246():442-449. PubMed ID: 31635836 [TBL] [Abstract][Full Text] [Related]
12. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. Wang B; Li J; Sun M; Sun L; Zhang X IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313 [TBL] [Abstract][Full Text] [Related]
13. Transcriptome-wide analysis of compression-induced microRNA expression alteration in breast cancer for mining therapeutic targets. Kim BG; Kang S; Han HH; Lee JH; Kim JE; Lee SH; Cho NH Oncotarget; 2016 May; 7(19):27468-78. PubMed ID: 27027350 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-31 controls G protein alpha-13 (GNA13) expression and cell invasion in breast cancer cells. Rasheed SA; Teo CR; Beillard EJ; Voorhoeve PM; Zhou W; Ghosh S; Casey PJ Mol Cancer; 2015 Mar; 14():67. PubMed ID: 25889182 [TBL] [Abstract][Full Text] [Related]
15. miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway. Lee J; Kim HE; Song YS; Cho EY; Lee A Breast Cancer Res Treat; 2019 Jul; 176(1):119-130. PubMed ID: 30989460 [TBL] [Abstract][Full Text] [Related]
16. miR-493-5p attenuates the invasiveness and tumorigenicity in human breast cancer by targeting FUT4. Zhao L; Feng X; Song X; Zhou H; Zhao Y; Cheng L; Jia L Oncol Rep; 2016 Aug; 36(2):1007-15. PubMed ID: 27375041 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic modifications, chromatin distribution and TP53 transcription in a model of breast cancer progression. Santos GC; da Silva AP; Feldman L; Ventura GM; Vassetzky Y; de Moura Gallo CV J Cell Biochem; 2015 Apr; 116(4):533-41. PubMed ID: 25358520 [TBL] [Abstract][Full Text] [Related]
18. Distinct karyotypes in three breast cancer cell lines --21PTCi, 21NTCi, and 21MT-1 --derived from the same patient and representing different stages of tumor progression. Xu J; Souter LH; Chambers AF; Rodenhiser DI; Tuck AB Cancer Genet Cytogenet; 2008 Oct; 186(1):33-40. PubMed ID: 18786440 [TBL] [Abstract][Full Text] [Related]
19. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789 [TBL] [Abstract][Full Text] [Related]
20. Pyridoxine 5'-phosphate oxidase is correlated with human breast invasive ductal carcinoma development. Ren W; Guan W; Zhang J; Wang F; Xu G Aging (Albany NY); 2019 Apr; 11(7):2151-2176. PubMed ID: 30982780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]